All News

How do you prevent RA in at-risk patient? Smoking cessation! Healthy weight and exercise! Diet! Periodontal health! 🚭🏋️🥕🦷 Education & follow-up! Not robustly proven to prevent/delay RA, but may be more important than early DMARD intervention! Kevin Deane, MD #RNL2023 @RheumNow

Eric Dein ericdeinmd ( View Tweet)

Natural history of RA by Kevin Deane #RLN23 ⁦@RheumNow⁩ https://t.co/ab0cafDblz
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. Stanley Cohen on JAKinibs: Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions @RheumNow #RNL2023 https://t.co/3ZZHr0akrR
Robert B Chao, MD doctorRBC ( View Tweet)
JAKi cycling, likely something we all do/consider in clinic. Dr. S. Cohen reviews the JAK-pot study which shows good, expected results between cycling in patients. #RNL2023 ⁦@RheumNow⁩ https://t.co/qBau79o0VQ
Dr. Rachel Tate uptoTate ( View Tweet)
Transcriptomic studies of Rx Refractory #RA pts shows increased gene expression of plasmacytoid dendritic cells (pDC) (reflecting expansion of pDC precursors) correlated well w/ Rx resistance. Type I IFN negatively correlated w pre-DC gene expression https://t.co/japvTnuTNu https://t.co/ad6ofbg3cO

Links:

Dr. John Cush RheumNow ( View Tweet)
Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases. https://t.co/jpxQggd89T https://t.co/zjer5QTN3C

Links:

Dr. John Cush RheumNow ( View Tweet)
immune.activity.cytokine.jpg

Itaconate - A Potential New Immunosuppressive

d EurekAlert!

Researchers have revealed the modulatory effect of the anti-inflammatory metabolite itaconate (ITA) on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.

Read Article
DMARDs,biologics,RA

Cost-Effective Use of Biological and Targeted Synthetic DMARDs

d Jack Cush, MD

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).

Read Article
hip.THR_.jpg

Optimal Timing of Elective Hip or Knee Arthroplasty

d ACR

The American College of Rheumatology (ACR) and the American Association of Hip and Knee Surgeons (AAHKS) released a summary of its new guideline titled “The Optimal Timing of Elective Hip or Knee Arthroplasty for Patients with Symptomatic Moderate to Severe Osteoarthritis or Osteonecrosis Who Have Failed Nonoperative Therapy.”

Read Article
Geo-epidemiology of Autoantibodies in Rheumatoid Arthritis A multinational study of RA patients shows a variety of post-translationally modified AMPA. While AMPA differed in different ethnic populations, their levels correlated with total serum IgG. https://t.co/QuA980svOO https://t.co/M7706bqxtl

Links:

Dr. John Cush RheumNow ( View Tweet)
joint.wrist_.pain_.CTS_.Carpal.jpg

Carpal Tunnel - Steroid injection vs. Night Splinting

d Jack Cush, MD

A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.

Read Article
10 yr study of 390 RA pts, of whom 160 (41%) had MTX-related gastrointestinal intolerance (GIS); meaning they D/C MTX and had EGD - H. pylori was significantly higher inMTX GIS pts; such pts had 3 fold higher odds of Rx w/ biologics or JAKi's https://t.co/RvrUErHyWe https://t.co/ea8Kq42oqW

Links:

Dr. John Cush RheumNow ( View Tweet)
Population study from Japan shows that Aging is an independent contributor for seronegative RA in patients who are female, have a nonsmoking history, and a BMI < 25. https://t.co/WWRGczmc4K https://t.co/ZHRIHlxDIK

Links:

Dr. John Cush RheumNow ( View Tweet)
antibody (Keep)

Geo-epidemiology of Autoantibodies in Rheumatoid Arthritis

d Jack Cush, MD

A multinational study of rheumatoid arthritis (RA) patients shows a variety of post-translationally modified anti-modified protein antibodies (AMPA). While AMPA differed in different ethnic populations, their levels correlated with total serum IgG.

Read Article
Managing Septic Arthritis in RA https://t.co/ccRZLCtl3S https://t.co/wS2KG1jAJl

Links:

Dr. John Cush RheumNow ( View Tweet)
ARTIS Swedish study of Cancer in RA or PSA pts (~15k pts) starting JAKi vs TNFi. With ~2 yrs F/U, the risk of Cancer (excluding NMSC) was similar betw JAKi and TNFi (HR 0.94; 0.65 to 1.38), but more incident NMSC w/ JAKi (HR 2.12; 1.15 to 3.89) at 2 yrs https://t.co/BiPWF1T0lZ https://t.co/nrmaCGBcce

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

NSAIDs in Pregnancy (3.3.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow.  This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.

Read Article
In #RA, Citrullination modulates antigen processing and presentation by exposing otherwise cryptic epitopes https://t.co/aciZe4KG6H https://t.co/i7twPvb5P4

Links:

Dr. John Cush RheumNow ( View Tweet)
Periodontal Mucosal Breaks Trigger RA Disease Activity Periodontal disease (PD) is more common in RA, especially those with anti-citrullinated protein antibodies (ACPAs). RA activity has been linked to the severity of PD and mucosal inflammation. https://t.co/eTDNqlOHyp https://t.co/VZoeqJmsr0

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 25 studies, betw 1985 - 2021, showed US average annual visits for RA=5.25 for US rheums (vs 3.3 ex-US) & 4.8 US non-rheums. SLE=3.24 & 12.3 for US non-Rheums. FM=1.8 for US rheums & 0.4 vs ex-US Rheums. Rheum Visits Decreased 1982 to 2019 https://t.co/WIXDXUCG60 https://t.co/s7W9gcd5dd

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.